Anti-VEGF treatment of corneal neovascularization

Ocular Surface

Volumn 9, Issue 4, 2011, Pages 227-238

  Keating, Anne M ^a   Jacobs, Deborah S ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Boston Foundation for Sight   (United States)

Author keywords

Anti VEGF agents; Bevacizumab; Corneal neovascularization; Intravitreal injection; Ranibizumab; Subconjunctival injection; Vascular endothelial growth factor (VEGF); VEGF inhibitors

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CYCLOSPORIN; CYCLOSPORIN A; DAPSONE; MOXIFLOXACIN; MP 0112; MYCOPHENOLIC ACID; PAZOPANIB; PEGAPTANIB; PF 04523665; PF 655; PLACENTAL GROWTH FACTOR; PREDNISOLONE ACETATE; PROMETHAZINE; RANIBIZUMAB; RITUXIMAB; SUNITINIB; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; CLINICAL PRACTICE; COMPUTER PROGRAM; CORNEA DISEASE; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EYE DISEASE; FOLLOW UP; HERPES SIMPLEX KERATITIS; HUMAN; KERATINIZATION; MUCOUS MEMBRANE PEMPHIGOID; NONHUMAN; OCULAR CICATRICIAL PEMPHIGOID; PENETRATING KERATOPLASTY; PERSISTENT EPITHELIAL DEFECT; PIGMENT DISORDER; PROSTHESIS; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; REVIEW; SLIT LAMP; SYMBLEPHARON; TRICHIASIS; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

EID: 80755184781     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(11)70035-0     Document Type: Review

References (48)

1. Chang J, Gabison EE, Kato T, Azar, DT. Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242-249 (Pubitemid 32751680)
2. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43:245-69 (Pubitemid 28558273)
3. Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 2010;117:1300-5.e7
4. Boisjoly HM, Tourigny R, Bazin R, et al. Risk factors of corneal graft failure. Ophthalmology 1993;100:1728-35 (Pubitemid 23335941)
5. BenEzra D, Griffin BW, Maftzir G, et al. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 1997;38:1954-62 (Pubitemid 27407514)
6. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41:2514-22 (Pubitemid 30624378)
7. Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 2000;19:526-33 (Pubitemid 30460894)
8. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 2006;103:11405-10 (Pubitemid 44156530)
9. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007;125:834-6 (Pubitemid 46919748)
10. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007;245:1577-1579 (Pubitemid 47423342)
11. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643-51 (Pubitemid 37236406)
12. Kerbal R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39 (Pubitemid 37328908)
13. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endotheliial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4 (Pubitemid 23132159)
14. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71 (Pubitemid 26026196)
15. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 20:158-65
16. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-8 (Pubitemid 351339405)
17. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9 (Pubitemid 27441066)
18. Rosenfeld PJ, Moshfeghi AA, Puliafito CA . Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5 (Pubitemid 41073112)
19. CATT Research Group, Martin DF, Maguire MG. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908
20. Oliveira HB, Sakimoto T, Javier JA, et al. VEGF Trapr1r2 suppresses experimental corneal angiogenesis. Eur J Ophthalmol 2010;20:48-54
21. Flach AJ. The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies. Trans Am Ophthalmol Soc 2008;106:138-45
22. Dastjerdi MH, Saban DR, Okanobo A, et al. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci 2010;51:2411-7
23. Bock F, Konig Y, Kruse F, et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008;246:281-4 (Pubitemid 351149633)
24. Uy HS, Chan PS, Ang RE . Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson Syndrome. Cornea 2008;27:70-3
25. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115:e33-e38
26. Galor A, Yoo SH. Corneal melt while using topical bevacizumab eye drops. Ophthalmic Surg Lasers Imaging 2010;9:1-3
27. Lim M, Jacobs DS, Rosenthal P, Carrasquillo KG. The Boston ocular surface prosthesis as a novel drug delivery system for bevacizumab. Semin Ophthalmol 2009;24:149-55
28. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical Bevacizumab in the treatment of corneal neovascularization. Arch Ophthalmol 2009;127:381-9
29. Jacobs DJ, Lim M, Carrasquillo KG, Rosenthal PR Bevacizumab for corneal neovascularization. Ophthalmology 2009 116: 592-593.
30. Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 2008;27:734-45
31. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008;27:142-7 (Pubitemid 351158729)
32. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008;27:992-5
33. Oh JY, Kim MK, Wee WR. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea 2009;28:1070-3
34. Symes RJ, Poole TRG. Corneal graft surgery combined with subconjunctival bevacizumab (Avastin). Cornea 2010;29:691-3
35. Harooni H, Reddy V, Root T, Ambati B. Bevacizumab for graft rejection. Ophthalmology 2007:114:1950
36. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg 2007;33:1991-3 (Pubitemid 47615364)
37. Shalam KV, Agarwal S, Brar VS, et al. Evaluation of cytotoxic effects of bevacizumab on human corneal cells. Cornea 2009;28:328-33
38. Bock F, Onderka J, Rummelt C, et al. Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 2009;50:2095-102
39. Hosney MH, Zayed MA, Shalaby AMM, Eissa IM. Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation. J Ocul Pharmacol Ther 2009;25:513-517
40. Mandalos A, Tsakpinis D, Karayannopoulou G, et al. The effect of subconjunctival ranibizumab on primary pterygium: a pilot study. Cornea 2001;29:1373-9
41. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125:1591-8 (Pubitemid 28256727)
42. Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008;62:779-86
43. Schucker C, Loke YK, Ehlken C, et al. Intravitreal bevacizumab (Avastin) vs ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 2011;95:308-17
44. Piltonen M, Planken A, Leskela O, et al. Vascular endothelial growth factor C acts as a neurotrophic factor for dopaminergic neurons in vitro and in vivo. Neuroscience 2011;Jul 14 (Epub ahead of print).
45. Schein OD, Rosenthal P, Ducharme C. A gas-permeable scleral contact lens for visual rehabilitation. Am J Ophthalmol 1990;109:318-22 (Pubitemid 20078953)
46. Romero-Rangel T, Stavrou P, Cotter J, et al. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 2000;130:25-32
47. Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft versus host disease. Cornea 2007;10:1195-9 (Pubitemid 350190910)
48. Stason WB, Razavi M, Jacobs DS, et al. Clinical benefits of the Boston Ocular Surface Prosthesis. Am J Ophthalmol 2010;149:54-61